Taysha Gene Therapies, Inc. (TSHA)
6.07
+0.05
(+0.83%)
USD |
NASDAQ |
Aug 27, 13:54
Taysha Gene Therapies Debt to Equity Ratio : 0.1469 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1469 |
| March 31, 2026 | 0.3247 |
| December 31, 2025 | 0.2856 |
| September 30, 2025 | 0.3174 |
| June 30, 2025 | 0.2419 |
| March 31, 2025 | 1.127 |
| December 31, 2024 | 0.8941 |
| September 30, 2024 | 0.7043 |
| June 30, 2024 | 0.5302 |
| March 31, 2024 | 1.127 |
| December 31, 2023 | 0.8154 |
| September 30, 2023 | -1.205 |
| June 30, 2023 | -1.604 |
| Date | Value |
|---|---|
| March 31, 2023 | -4.003 |
| December 31, 2022 | 63.15 |
| September 30, 2022 | 5.687 |
| June 30, 2022 | 1.932 |
| March 31, 2022 | 1.245 |
| December 31, 2021 | 0.6615 |
| September 30, 2021 | 0.3876 |
| June 30, 2021 | 0.1405 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Altimmune, Inc. | 0.076 |
| Protalix Biotherapeutics, Inc. | 0.1289 |
| Humacyte, Inc. | 2.117 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 470.43M |
| Total Liabilities (Quarterly) | 83.17M |
| Shareholders Equity (Quarterly) | 387.27M |
| Current Ratio | 17.76 |
| Net Debt Paydown Yield | 0.05% |